1Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription [J]. Cell, 2002,108(4):475-487.
2Jain S, Zain J. Romidepsin in the treatment of cutaneous Tcelt lymphoma [J]. J Blood Med,2011,2 : 37-47.
3Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases [ J ]. Cancer Res, 2002,62 ( 17 ) :4916-4921.
4Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma [ J ]. J Clin Oncol,2009,27 (32) : 5410-5417.
5Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes [ J ]. Biol Pharm Bull, 2005,28 ( 1 ) : 124- 129.
6Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a muhicenter, international, pivotal study of romidep- sin in refractory cutaneous T-cell lymphoma[ J]. J Clin On- col,2010,28 (29) :4485-4491.
7Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or re- fractory peripheral T-cell lymphoma after prior systemic therapy[J1. J Clin 0ncol,2012,30(6):631-636.
8Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma [J ]. Blood,2011,117 (22) : 5827-5834.
9Grant C, Rahman F, Piekarz R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors [J]. Expert Rev Anticancer Ther, 2010, 10(7) : 997-1008.
10Piekarz RL, Frye AR, Wright J J, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma[J]. Clin Cancer Res, 2006,12 ( 12 ) : 3762-3773.
